Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …

The sixth edition of the Japanese Gastric Cancer Treatment Guidelines was completed in
July 2021, incorporating new evidence that emerged after publication of the previous …

Cancers originating in the esophagus or esophagogastric junction constitute a major global
health problem. Esophageal cancers are histologically classified as squamous cell …

More than 1 million (1 089 103) new cases of gastric cancer were estimated globally in
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …